XML 29 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2019
Accounting Policies [Abstract]  
The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:

The following table provides information about disaggregated revenue by product mix for the years ended December 31, 2019, 2018, and 2017:

 

 

 

 

 

 

 

 

 

 

For the Years Ended December 31,

 

 

 

2019

 

 

2018

 

 

2017

 

Prescription vitamins

 

$

9,885,493

 

 

$

15,041,259

 

 

$

16,744,831

 

IMVEXXY

 

 

16,252,045

 

 

 

1,058,201

 

 

 

—

 

BIJUVA

 

 

1,836,443

 

 

 

—

 

 

 

—

 

ANNOVERA

 

 

6,166,556

 

 

 

—

 

 

 

—

 

License revenue

 

 

15,506,400

 

 

 

—

 

 

 

—

 

OTC products

 

 

—

 

 

 

—

 

 

 

32,882

 

Net revenue

 

$

49,646,937

 

 

$

16,099,460

 

 

$

16,777,713

 
The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.

The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.

 

 

 

 

 

 

 

 

 

As of December 31,

 
 

 

2019

 

 

2018

 

 

2017

 

Stock options

 

 

25,030,234

 

 

 

20,872,824

 

 

 

23,365,225

 

Warrants

 

 

1,832,571

 

 

 

3,007,571

 

 

 

3,115,905

 

Restricted stock awards

 

 

1,240,000

 

 

 

1,040,000

 

 

 

—

 
 

 

 

28,102,805

 

 

 

24,920,395

 

 

 

26,481,130